{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:16:55Z","timestamp":1791379015935,"version":"4.3.2"},"reference-count":30,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To provide an updated evaluation of the efficacy and safety of asenapine in bipolar disorder using evidence from randomized controlled trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An updated systematic review and pairwise meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to October 2025. Randomized controlled trials comparing asenapine with placebo were included. The primary outcome was change from baseline in Young Mania Rating Scale (YMRS) scores. Secondary outcomes included Clinical Global Impressions\u2013Bipolar Severity (CGI-BP-S) overall and mania scores, Montgomery\u2013\u00c5sberg Depression Rating Scale (MADRS) scores, and incidence of adverse events. Random-effects models with restricted maximum-likelihood estimation and Hartung\u2013Knapp adjustment were applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five trials comprising 1,593 participants were included. Asenapine significantly reduced manic symptoms compared with placebo (YMRS mean difference \u22124.00, 95% CI \u22125.55 to \u22122.45). Significant improvements were observed in CGI-BP-S overall severity (\u22120.51, 95% CI \u22120.78 to \u22120.24) and mania scores (\u22120.47, 95% CI \u22120.77 to \u22120.16). modest improvement was observed in MADRS scores (\u22121.38, 95% CI \u22122.52 to \u22120.24). Adverse events were more frequent with asenapine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Asenapine is an effective short-term treatment for acute mania in bipolar disorder, with tolerability considerations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.64719\/pb.16572","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:16:27Z","timestamp":1773260187000},"page":"8-28","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"],"prefix":"10.64719","volume":"56","author":[{"given":"Muneeb Ahmad","family":"Muneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Hafsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umair","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moneeba","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zain","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warda Fatima","family":"Shafee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suboor Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanana","family":"Nasir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Khubair","family":"Farrukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ume","family":"Khansa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafsa Arshad Azam","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Tehseen","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Singh B, Swartz HA, Cuellar-Barboza AB et al. Bipolar disorder. The Lancet. 2025;406(10506):963\u2013978. doi: 10.1016\/S0140-6736(25)01140-7.","DOI":"10.1016\/S0140-6736(25)01140-7"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Nierenberg AA, Agustini B, K\u00f6hler-Forsberg O et al. Diagnosis and treatment of bipolar disorder: a review. JAMA. 2023;330(14):1370. doi: 10.1001\/jama.2023.18588.","DOI":"10.1001\/jama.2023.18588"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Jiang J, Chen Y, Lin Z, Liu S, Chen X, Chen Q. Global, regional, and national burden of bipolar disorder, 1990\u20132021: analysis of data from the global burden of disease study 2021. Journal of Affective Disorders. 2025;389:119638. doi: 10.1016\/j.jad.2025.119638.","DOI":"10.1016\/j.jad.2025.119638"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Kato T. Current understanding of bipolar disorder: toward integration of biological basis and treatment strategies. Psychiatry and Clinical Neurosciences. 2019;73(9):526\u2013540. doi: 10.1111\/pcn.12852.","DOI":"10.1111\/pcn.12852"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Muhammad I, Ghaniya R, Abdul H. Addressing the stigma of bipolar disorder in Pakistan: a matter of public health importance. Journal of the Pakistan Medical Association. 2024;74(10):1910\u20131911. doi: 10.47391\/JPMA.11155.","DOI":"10.47391\/JPMA.11155"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. The Lancet. 2016;387(10027):1561\u20131572. doi: 10.1016\/S0140-6736(15)00241-X.","DOI":"10.1016\/S0140-6736(15)00241-X"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Whiteford HA, Ferrari AJ, Degenhardt L, Feigin V, Vos T. The global burden of mental, neurological and substance use disorders: an analysis from the global burden of disease study 2010. PLoS ONE. 2015;10(2):e0116820. doi: 10.1371\/journal.pone.0116820.","DOI":"10.1371\/journal.pone.0116820"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Serafini G, Pardini M, Monacelli F et al. Neuroprogression as an illness trajectory in bipolar disorder: a selective review of the current literature. Brain Sciences. 2021;11(2):276. doi: 10.3390\/brainsci11020276.","DOI":"10.3390\/brainsci11020276"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Vieta E, Langosch JM, Figueira ML et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd) International Journal of Neuropsychopharmacology. 2013;16(8):1719\u20131732. doi: 10.1017\/S1461145713000278.","DOI":"10.1017\/S1461145713000278"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Balaraman R, Gandhi H. Asenapine, a new sublingual atypical antipsychotic. Journal of Pharmacology and Pharmacotherapeutics. 2010;1(1):60\u201361. doi: 10.4103\/0976-500X.64538.","DOI":"10.4103\/0976-500X.64538"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Aguglia A, Mineo L, Rodolico A, Signorelli MS, Aguglia E. Asenapine in the management of impulsivity and aggressiveness in bipolar disorder and comorbid borderline personality disorder: an open-label uncontrolled study. International Clinical Psychopharmacology. 2018;33(3):121\u2013130. doi: 10.1097\/YIC.0000000000000206.","DOI":"10.1097\/YIC.0000000000000206"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Goes FS. Diagnosis and management of bipolar disorders. BMJ. 2023;381:e073591. doi: 10.1136\/bmj-2022-073591.","DOI":"10.1136\/bmj-2022-073591"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021:n71. doi: 10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"ref14","unstructured":"Organon and Co. Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P06107) 2024 (Clinical Trial Registration No. NCT01244815). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT01244815."},{"key":"ref15","unstructured":"Study Results | NCT00145470 | 12 Week Study of the Safety\/Efficacy of Asenapine When Added to Lithium\/Valproate in the Treatment of Bipolar Disorder (A7501008 \/ P05844 \/ MK-8274-017) | ClinicalTrials.gov. (n.d.). Retrieved December 30, 2025, from https:\/\/clinicaltrials.gov\/study\/NCT00145470."},{"key":"ref16","unstructured":"Study Results | NCT00764478 | Fixed-dose Safety and Efficacy Study of Asenapine for the Treatment of Acute Manic or Mixed Episode in Bipolar 1 Disorder (P05691) | ClinicalTrials.gov. (n.d.). Retrieved December 30, 2025, from https:\/\/clinicaltrials.gov\/study\/NCT00764478."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disorders. 2009;11(7):673\u2013686. doi: 10.1111\/j.1399-5618.2009.00748.x.","DOI":"10.1111\/j.1399-5618.2009.00748.x"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. Journal of Affective Disorders. 2010;122(1\u20132):27\u201338. doi: 10.1016\/j.jad.2009.12.028.","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Lukasiewicz M, Gerard S, Besnard A et al. Young Mania Rating Scale: how to interpret the numbers? Determination of a severity threshold and of the minimal clinically significant difference in the EMBLEM cohort. International Journal of Methods in Psychiatric Research. 2013;22(1):46\u201358. doi: 10.1002\/mpr.1379.","DOI":"10.1002\/mpr.1379"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Samara MT, Levine SZ, Leucht S. Linkage of Young Mania Rating Scale to clinical global impression scale to enhance utility in clinical practice and research trials. Pharmacopsychiatry. 2023;56(01):18\u201324. doi: 10.1055\/a-1841-6672.","DOI":"10.1055\/a-1841-6672"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Vita A, De Peri L, Siracusano A, Sacchetti E. Efficacy and tolerability of asenapine for acute mania in bipolar I disorder: meta-analyses of randomized-controlled trials. International Clinical Psychopharmacology. 2013;28(5):219\u2013227. doi: 10.1097\/YIC.0b013e32836290d2.","DOI":"10.1097\/YIC.0b013e32836290d2"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kishi T, Ikuta T, Matsuda Y et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Molecular Psychiatry. 2022;27(2):1136\u20131144. doi: 10.1038\/s41380-021-01334-4.","DOI":"10.1038\/s41380-021-01334-4"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet. 2011;378(9799):1306\u20131315. doi: 10.1016\/S0140-6736(11)60873-8.","DOI":"10.1016\/S0140-6736(11)60873-8"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Azorin JM, Sapin C, Weiller E. Effect of asenapine on manic and depressive symptoms in bipolar I patients with mixed episodes: results from post hoc analyses. Journal of Affective Disorders. 2013;145(1):62\u201369. doi: 10.1016\/j.jad.2012.07.013.","DOI":"10.1016\/j.jad.2012.07.013"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Landbloom RL, Mackle M, Wu X et al. Asenapine: Efficacy and safety of 5 and 10 mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. Journal of Affective Disorders. 2016;190:103\u2013110. doi: 10.1016\/j.jad.2015.06.059.","DOI":"10.1016\/j.jad.2015.06.059"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Zhao J, Cazorla P, Mackle M, Szegedi A. Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis. Neuropsychiatric Disease and Treatment. 2013;9:409\u2013413. doi: 10.2147\/NDT.S38390.","DOI":"10.2147\/NDT.S38390"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Shahid M, Walker G, Zorn S, Wong E. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. Journal of Psychopharmacology. 2009;23(1):65\u201373. doi: 10.1177\/0269881107082944.","DOI":"10.1177\/0269881107082944"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opinion on Drug Safety. 2014:1\u201328. doi: 10.1517\/14740338.2014.908183.","DOI":"10.1517\/14740338.2014.908183"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Ketter TA, Durgam S, Landbloom R, Mackle M, Wu X, Mathews M. Long-term safety and tolerability of asenapine: a double-blind, uncontrolled, long-term extension trial in adults with an acute manic or mixed episode associated with bipolar I disorder. Journal of Affective Disorders. 2017;207:384\u2013392. doi: 10.1016\/j.jad.2016.09.037.","DOI":"10.1016\/j.jad.2016.09.037"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Szegedi A, Zhao J, Van Willigenburg A, Nations KR, Mackle M, Panagides J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry. 2011;11(1):101. doi: 10.1186\/1471-244X-11-101.","DOI":"10.1186\/1471-244X-11-101"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:36:30Z","timestamp":1791315390000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/efficacy-and-safety-of-asenapine-in-bipolar-disorder-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,3,9]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.16572","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]}}}